argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter of 2025 and provided a comprehensive business update. CEO Statement…
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal year 2024, reflecting solid product performance across key markets. Core…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange rates (CER), reaching DKK 38.8 billion. Sales in the US…
Sanofi Showcases Expansive Respiratory Innovation and Scientific Leadership at ATS 2025 with Robust Clinical Data from Dupixent and Immunology Pipeline Sanofi is poised to make a major impact at the 2025 American Thoracic Society (ATS) International Conference, taking place from…
Bio-Rad Announces Financial Results for the First Quarter of 2025 Bio-Rad Laboratories, Inc. , a global leader in life science research and clinical diagnostics, released its financial results for the first quarter of 2025, reporting a modest decline in sales…
PCI Pharma Acquires Ajinomoto Althea as Part of $1B Investment to Boost U.S. Aseptic Fill-Finish Capacity PCI Pharma Services, a globally recognized contract development and manufacturing organization (CDMO) specializing in the development and commercialization of innovative biopharmaceutical therapies, has officially…
Sunflower Therapeutics Announces Sales Agreement with Optimal Biotech Group Sunflower Therapeutics, a public benefit corporation with a mission to transform global access to protein manufacturing capacity, has taken a significant step toward commercial expansion with the announcement of a new…
Glaukos Reports Financial Results for First Quarter 2025 Glaukos Corporation , a global ophthalmic pharmaceutical and medical technology innovator, delivered a powerful performance in the first quarter of 2025, signaling a robust start to the fiscal year. With record-breaking revenue…
Sage Therapeutics Reports Q1 2025 Results and Pipeline Highlights Sage Therapeutics, Inc., a biopharmaceutical company committed to advancing brain health, released its financial results and operational highlights for the first quarter ended March 31, 2025. The company’s update underscores significant…
Ray Therapeutics Gets $8M Grant to Work on New Gene Therapy for Vision Loss Disease In a significant milestone for the field of regenerative medicine and vision restoration, Ray Therapeutics—a clinical-stage biotechnology company specializing in optogenetic gene therapies—has been awarded…
Gilead Sciences Reports Financial Results for First Quarter 2025 Gilead Sciences, Inc. (Nasdaq: GILD) has unveiled its financial and operational performance for the first quarter of 2025, underscoring a steady start to the year that reflects both commercial momentum and…
GSK Invests $4 Million in Adult Vaccination Efforts, Doubling Down with New 2025 Commitment In a major push to improve adult immunization rates across the United States, GSK plc has announced the 15 recipients of its 2024 COiMMUNITY Initiative grant…